page | |
EDITORIALS |
288 | There is more to severe asthma associated with obesity than inflammation
|
290 | COPD: COagulation-associated Pulmonary Disease?
|
292 | Mapping air pollution and idiopathic pulmonary fibrosis
Michael J Abramson PhD, FRACP, FAFPHM; E Haydn Walters DM, DSc, FRCP, FRACP
10.1111/resp.14004 |
294 | Obstructive sleep apnoea phenotypes: The many faces of a public health monolith
|
COMMENTARY |
296 | Impact of recent catastrophic bushfires on people with asthma in Australia: Health, social and financial burdens
Dinh Bui PhD; Sharon Davis PhD; Anthony Flynn MSc; Rose Bell BSc; Shyamali Dharmage PhD
10.1111/resp.14013 |
INVITED REVIEW SERIES |
298 | Natural history and mechanisms of COPD
Peter Lange, Engi Ahmed, Zakaria Mohamed Lahmar, Fernando J Martinez, Arnaud Bourdin
10.1111/resp.14007 |
322 | Epidemiology, clinical spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region
Kin On Kwok Ying Huang Margaret Ting Fong Tsoi Arthur Tang Samuel Yeung Shan Wong Wan In Wei David Shu Cheong Hui
10.1111/resp.14026 |
ORIGINAL ARTICLES |
Asthma and Allergy |
334 |
Central airway collapse is related to obesity independent of asthma phenotype
Swati A Bhatawadekar, Ubong Peters, Ryan R Walsh, Nirav Daphtary, Erick S MacLean, Vitor Mori, Kevin Hodgdon, C Matthew Kinsey, David A Kaminsky, Jason H T Bates, Anne E Dixon
10.1111/resp.14005
We compared collapsibility of central airways in lean and obese individuals with and without asthma by CT from changes in airway luminal area and circularity at reduced lung volume. Our results indicate that obesity is characterized by excessive central airway collapse. |
COPD |
342 | Coagulation markers as predictors for clinical events in COPD
Gunnar R Husebø, Esteban C Gabazza, Corina D'Alessandro Gabazza, Taro Yasuma, Masaaki Toda, Marianne Aanerud, Rune Nielsen Per S Bakke, Tomas M L Eagan
10.1111/resp.13971
Elevated coagulation markers are potential predictors of higher mortality and also a shorter time to the first AECOPD as well as a higher 3-year AECOPD rate. Activation of the coagulation system is increased during COPD exacerbations. |
Environmental and Occupational Lung Disease |
352 | Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers
Jessica Germaine Shull, Maria Teresa Pay, Carla Lara Compte, Miriam Olid, Guadalupe Bermudo, Karina Portillo, Jacobo Sellarés, Eva Balcells, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Diana Badenes-Bonet, Rosana Blavia, Pilar Rivera-Ortega, Amalia Moreno, Jordi Sans, Damià Perich, Silvia Barril, Leonardo Esteban, Laia Garcia-Bellmunt, Jordi Esplugas, Guillermo Suarez-Cuartin, Jaume Bordas-Martinez, Diego Castillo, Rosa Jolis, Inma Salvador, Saioa Eizaguirre Anton, Ana Villar, Alejandro Robles-Perez, M Josefa Cardona, Enric Barbeta, Maria Guadalupe Silveira, Claudia Guevara, Jordi Dorca, Antoni Rosell, Patricio Luburich, Roger Llatjós, Oriol Jorba, Maria Molina-Molina
10.1111/resp.13973
This study identifies geographic regions of notable air pollution, juxtaposed over locations with higher prevalence of idiopathic pulmonary fibrosis (IPF). Certain areas with elevated air pollutants may be deserving greater analysis for screening of IPF and optimizing early identification. Prospective studies are required for evaluating air pollution as an IPF risk factor. |
Interstitial Lung Disease |
360 | Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: A randomized controlled trial
Miao Zhou, Hailong Zhang, Fenglei Li, Zhefeng Yu, Chengbo Yuan, Brian Oliver, Jiansheng Li
10.1111/resp.13972
This is a randomized clinical trial evaluating the effects of PD, a TCM PR programme, in patients with IPF. PD was associated with a clinically meaningful difference in the 6MWD. |
370 |
Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial
Tomoyuki Fujisawa, Hironao Hozumi, Yosuke Kamiya, Yusuke Kaida, Taisuke Akamatsu, Hideki Kusagaya, Yasuomi Satake, Kazutaka Mori, Masashi Mikamo, Hiroyuki Matsuda, Koshi Yokomura, Naoki Koshimizu, Mikio Toyoshima, Shiro Imokawa, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
10.1111/resp.13978
This is the first prospective trial to compare the efficacy of two different regimens, PSL plus TAC and PSL plus CsA, in patients with PM/DM-ILD. PSL plus TAC may achieve a better progression-free survival rate at 52 weeks than PSL plus CsA. |
Sleep and Ventilation |
378 | Clusters of sleep apnoea phenotypes: A large pan-European study from the European Sleep Apnoea Database (ESADA)
Sébastien Bailly, Ludger Grote, Jan Hedner, Sofia Schiza, Walter T McNicholas, Ozen K Basoglu, Carolina Lombardi, Zoran Dogas, Gabriel Roisman, Athanasia Pataka, Maria R Bonsignore, Jean-Louis Pepin, on behalf of the ESADA Study Group
10.1111/resp.13969
A cluster analysis of a pan-European database of over 23 000 OSA patients found eight distinct clinical phenotypes, with clear gender-based differences and implications for more personalized treatment prescriptions. |
FORUM AND DEBATE |
Scientific Letter |
388 | Long-term follow-up after intrapleural tPA/DNase therapy for pleural infection
Natalia D Popowicz, Francesco Piccolo, Elaine Yap, Conroy Wong, Ben Brockway, Nicola A Smith, Cameron Sullivan, Arthur W Musk, Y C Gary Lee
10.1111/resp.14015 |
Correspondences |
392 | Multidisciplinary pulmonary embolism response team in China: A nationwide survey
Xiao Wang MD; Qingwei Ji MD; Kenneth Rosenfield MD; Victor Tapson MD; Shaoping Nie MD, PhD
10.1111/resp.14011 |
394 | Features of humidifier lung and comparison with summer-type hypersensitivity pneumonitis
Masafumi Shimoda MD; Kozo Morimoto MD, PhD; Yoshiaki Tanaka MD; Koji Furuuchi MD; Takeshi Osawa MD; Ryozo Yano MD; Hiroyuki Kokutou MD; Kozo Yoshimori MD; Ken Ohta MD, PhD
10.1111/resp.14014 |
LETTER FROM ASIA-PACIFIC AND BEYOND |
396 | Letter from Myanmar
|
CORRIGENDUM |
CORRIGENDUM |
398 | This article corrects:
|